Routine Oxygen Therapy Does Not Improve Health-Related Quality of Life in Patients With Acute Myocardial Infarction-Insights From the Randomized DETO2X-AMI Trial

Robin Hofmann, Tamrat Befekadu Abebe, Johan Herlitz, Stefan K James, David Erlinge, Troels Yndigegn, Joakim Alfredsson, Thomas Kellerth, Annica Ravn-Fischer, Sebastian Völz, Jörg Lauermann, Tomas Jernberg, Bertil Lindahl, Sophie Langenskiöld, Robin Hofmann, Tamrat Befekadu Abebe, Johan Herlitz, Stefan K James, David Erlinge, Troels Yndigegn, Joakim Alfredsson, Thomas Kellerth, Annica Ravn-Fischer, Sebastian Völz, Jörg Lauermann, Tomas Jernberg, Bertil Lindahl, Sophie Langenskiöld

Abstract

Background: After decades of ubiquitous oxygen therapy in all patients with acute myocardial infarction (MI), recent guidelines are more restrictive based on lack of efficacy in contemporary trials evaluating hard clinical outcomes in patients without hypoxemia at baseline. However, no evidence regarding treatment effects on health-related quality of life (HRQoL) exists. In this study, we investigated the impact of routine oxygen supplementation on HRQoL 6-8 weeks after hospitalization with acute MI. Secondary objectives included analyses of MI subtypes, further adjustment for infarct size, and oxygen saturation at baseline and 1-year follow-up. Methods: In the DETermination of the role of Oxygen in suspected Acute Myocardial Infarction (DETO2X-AMI) trial, 6,629 normoxemic patients with suspected MI were randomized to oxygen at 6 L/min for 6-12 h or ambient air. In this prespecified analysis, patients younger than 75 years of age with confirmed MI who had available HRQoL data by European Quality of Life Five Dimensions questionnaire (EQ-5D) in the national registry were included. Primary endpoint was the EQ-5D index assessed by multivariate linear regression at 6-10 weeks after MI occurrence. Results: A total of 3,086 patients (median age 64, 22% female) were eligible, 1,518 allocated to oxygen and 1,568 to ambient air. We found no statistically significant effect of oxygen therapy on EQ-5D index (-0.01; 95% CI: -0.03-0.01; p = 0.23) or EQ-VAS score (-0.57; 95% CI: -1.88-0.75; p = 0.40) compared to ambient air after 6-10 weeks. Furthermore, no significant difference was observed between the treatment groups in EQ-5D dimensions. Results remained consistent across MI subtypes and at 1-year follow-up, including further adjustment for infarct size or oxygen saturation at baseline. Conclusions: Routine oxygen therapy provided to normoxemic patients with acute MI did not improve HRQoL up to 1 year after MI occurrence. Clinical Trial Registration: ClinicalTrials.gov number, NCT01787110.

Keywords: Registry-based randomized clinical trial; health-realted quality of life; myocardial infarction; oxygen therapy; patient reported clinical outcomes; secondary prevention.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hofmann, Befekadu Abebe, Herlitz, James, Erlinge, Yndigegn, Alfredsson, Kellerth, Ravn-Fischer, Völz, Lauermann, Jernberg, Lindahl and Langenskiöld.

Figures

Figure 1
Figure 1
Enrollment, randomization, and analysis (study flow chart). Eligible patients with suspected myocardial infarction were evaluated for inclusion in the main study, randomly assigned to a study group (oxygen vs. ambient air), and analyzed during the study period. In the present prespecified subgroup analysis, only patients with confirmed MI below the age of 75 who are subject for follow-up in the national registry were included. DETO2X-AMI, Determination of the Role of Oxygen in Acute Myocardial Infarction; MI, myocardial infarction; EQ-5D, European Quality of Life Five Dimensions questionnaire; DETO2X-HRQoL, DETO2X health-related quality of life subgroup analysis; STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.
Figure 2
Figure 2
Cumulative distribution of EQ-5D index for patients with confirmed myocardial infarction at weeks 6–10. Cumulative distribution of EQ-5D index. For each EQ-5D index value displayed, the graph shows the proportion of patients below that cut point.
Figure 3
Figure 3
Cumulative distribution of EQ-VAS for patients with confirmed myocardial infarction at weeks 6–10. Cumulative distribution of EQ-VAS. For each EQ-5D index value displayed, the graph shows the proportion of patients below that cut point.
Figure 4
Figure 4
EQ-5D dimensions on visit 1. The EQ-5D is a generic instrument that measures patients' health-related quality of live five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The patients' self-rate their current health state using a three-item ordinal response scale (no/moderate/severe problem). p-values for comparison of oxygen vs. ambient air were non-significant for all dimensions. Missing observations: 8.2% in the oxygen group and 7.7% in the ambient-air group.

References

    1. Kones R. Oxygen therapy for acute myocardial infarction-then and now. A century of uncertainty. Am J Med. (2011) 124:1000–5. 10.1016/j.amjmed.2011.04.034
    1. Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S, et al. . Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? Eur Heart J. (2013) 34:1630–5. 10.1093/eurheartj/eht110
    1. Cabello JB, Burls A, Emparanza JI, Bayliss SE, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. (2016) 12:CD007160. 10.1002/14651858.CD007160.pub4
    1. Burls A, Emparanza JI, Quinn T, Cabello JB. Oxygen use in acute myocardial infarction: an online survey of health professionals' practice and beliefs. Emerg Med J. (2010) 27:283–6. 10.1136/emj.2009.077370
    1. Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. J Am Coll Cardiol. (2010) 56:1013–6. 10.1016/j.jacc.2010.04.052
    1. Sepehrvand N, Ezekowitz JA. Oxygen therapy in patients with acute heart failure: friend or foe? JACC Heart Fail. (2016) 4:783–90. 10.1016/j.jchf.2016.03.026
    1. Wang XX, Sha XL, Li YL, Li CL, Chen SH, Wang JJ, et al. . Lung injury induced by short-term mechanical ventilation with hyperoxia and its mitigation by deferoxamine in rats. BMC Anesthesiol. (2020) 20:188. 10.1186/s12871-020-01089-5
    1. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. . Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. (2015) 131:2143–50. 10.1161/CIRCULATIONAHA.114.014494
    1. Chu DK, Kim LH, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. . Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. (2018) 391:1693–705. 10.1016/S0140-6736(18)30479-3
    1. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. . Oxygen therapy in suspected acute myocardial infarction. N Engl J Med. (2017) 377:1240–9. 10.1056/NEJMoa1706222
    1. Jernberg T, Lindahl B, Alfredsson J, Berglund E, Bergstrom O, Engstrom A, et al. . Long-term effects of oxygen therapy on death or hospitalization for heart failure in patients with suspected acute myocardial infarction. Circulation. (2018) 138:2754–62. 10.1161/CIRCULATIONAHA.118.036220
    1. Sparv D, Hofmann R, Gunnarsson A, James S, Hedberg C, Lauermann J, et al. . The analgesic effect of oxygen in suspected acute myocardial infarction: a substudy of the DETO2X-AMI trial. JACC Cardiovasc Interv. (2018) 11:1590–7. 10.1016/j.jcin.2018.04.043
    1. Andell P, James S, Ostlund O, Yndigegn T, Sparv D, Pernow J, et al. . Oxygen therapy in suspected acute myocardial infarction and concurrent normoxemic chronic obstructive pulmonary disease: a prespecified subgroup analysis from the DETO2X-AMI trial. Eur Heart J Acute Cardiovasc Care. (2019) 9:984–92. 10.1177/2048872619848978
    1. Hofmann R, Tornvall P, Witt N, Alfredsson J, Svensson L, Jonasson L, et al. . Supplemental oxygen therapy does not affect the systemic inflammatory response to acute myocardial infarction. J Intern Med. (2018) 283:334–45. 10.1111/joim.12716
    1. Hofmann R, Witt N, Lagerqvist B, Jernberg T, Lindahl B, Erlinge D, et al. . Oxygen therapy in ST-elevation myocardial infarction. Eur Heart J. (2018) 39:2730–9. 10.1093/eurheartj/ehy326
    1. Nystrom T, James SK, Lindahl B, Ostlund O, Erlinge D, Herlitz J, et al. . Oxygen therapy in myocardial infarction patients with or without diabetes: a predefined subgroup analysis from the DETO2X-AMI trial. Diabetes Care. (2019) 42:2032–41. 10.2337/dc19-0590
    1. James SK, Erlinge D, Herlitz J, Alfredsson J, Koul S, Frobert O, et al. . Effect of oxygen therapy on cardiovascular outcomes in relation to baseline oxygen saturation. JACC Cardiovasc Interv. (2020) 13:502–13. 10.1016/j.jcin.2019.09.016
    1. Samadani U, Affana CK. Oxygen therapy in suspected acute myocardial infarction. N Engl J Med. (2018) 378:200–1. 10.1056/NEJMc1714937
    1. Levine DA, Davydow DS, Hough CL, Langa KM, Rogers MA, Iwashyna TJ. Functional disability and cognitive impairment after hospitalization for myocardial infarction and stroke. Circ Cardiovasc Qual Outcomes. (2014) 7:863–71. 10.1161/HCQ.0000000000000008
    1. Casati A, Fanelli G, Pietropaoli P, Proietti R, Tufano R, Montanini S, et al. . Monitoring cerebral oxygen saturation in elderly patients undergoing general abdominal surgery: a prospective cohort study. Eur J Anaesthesiol. (2007) 24:59–65. 10.1017/S0265021506001025
    1. Yndigegn T, Hofmann R, Jernberg T, Gale CP. Registry-based randomised clinical trial: efficient evaluation of generic pharmacotherapies in the contemporary era. Heart. (2018) 104:1562–7. 10.1136/heartjnl-2017-312322
    1. Hofmann R, James SK, Svensson L, Witt N, Frick M, Lindahl B, et al. . DETermination of the role of oxygen in suspected acute myocardial infarction trial. Am Heart J. (2014) 167:322–8. 10.1016/j.ahj.2013.09.022
    1. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, et al. . The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. (2010) 96:1617–21. 10.1136/hrt.2010.198804
    1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. . Third universal definition of myocardial infarction. Eur Heart J. (2012) 33:2551–67. 10.1093/eurheartj/ehs184
    1. Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, et al. . Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. (2016) 31:125–36. 10.1007/s10654-016-0117-y
    1. O'gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. (2013) 127:e362–425. 10.1161/CIR.0b013e3182742c84
    1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. . 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. (2014) 130:2354–94. 10.1161/CIR.0000000000000133
    1. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. . Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. (2018) 39:3766–76. 10.1093/eurheartj/ehy554
    1. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. (2010) 8:13. 10.1186/1477-7525-8-13
    1. Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. (1990) 16:199–208. 10.1016/0168-8510(90)90421-9
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. (1997) 35:1095–108. 10.1097/00005650-199711000-00002
    1. Feng Y, Parkin D, Devlin NJ. Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual Life Res. (2014) 23:977–89. 10.1007/s11136-013-0537-z
    1. Sepehrvand N, James SK, Stub D, Khoshnood A, Ezekowitz JA, Hofmann R. Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. Heart. (2018) 104:1691–8. 10.1136/heartjnl-2018-313089
    1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. (2018) 39:119–77. 10.1093/eurheartj/ehx393
    1. Fisher J, Wijeysundera DN. Routine supplementary oxygen for myocardial infarction: from unsettled to unsettling. JACC Cardiovasc Interv. (2020) 13:514–6. 10.1016/j.jcin.2019.11.010
    1. Norlund F, Lissaker C, Wallert J, Held C, Olsson EM. Factors associated with emotional distress in patients with myocardial infarction: results from the SWEDEHEART registry. Eur J Prev Cardiol. (2018) 25:910–20. 10.1177/2047487318770510
    1. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. (2001) 10:621–35. 10.1023/A:1013171831202
    1. Azmi S, Goh A, Fong A, Anchah L. Quality of life among patients with acute coronary syndrome in Malaysia. Value Health Reg Issues. (2015) 6:80–3. 10.1016/j.vhri.2015.03.015
    1. Gencer B, Rodondi N, Auer R, Nanchen D, Räber L, Klingenberg R, et al. . Health utility indexes in patients with acute coronary syndromes. Open Heart. (2016) 3:e000419. 10.1136/openhrt-2016-000419
    1. Schweikert B, Hunger M, Meisinger C, König HH, Gapp O, Holle R. Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general population. Eur Heart J. (2009) 30:436–43. 10.1093/eurheartj/ehn509
    1. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. (2005) 14:1523–32. 10.1007/s11136-004-7713-0
    1. Zughaft D, Bhiladvala P, Van Dijkman A, Harnek J, Madsen Hardig B, Bjork J, et al. . The analgesic effect of oxygen during percutaneous coronary intervention (the OXYPAIN Trial). Acute Card Care. (2013) 15:63–8. 10.3109/17482941.2013.822083
    1. Roffe C, Nevatte T, Sim J, Bishop J, Ives N, Ferdinand P, et al. . Effect of routine low-dose oxygen supplementation on death and disability in adults with acute stroke: the stroke oxygen study randomized clinical trial. JAMA. (2017) 318:1125–35. 10.1001/jama.2017.11463
    1. Brazier J, Rowen D, Karimi M, Peasgood T, Tsuchiya A, Ratcliffe J. Experience-based utility and own health state valuation for a health state classification system: why and how to do it. Eur J Health Econom. (2018) 19:881–91. 10.1007/s10198-017-0931-5
    1. Torrance GW, Feeny D, Furlong W. Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States? Thousand Oaks, CA: Sage Publications; (2001). 10.1177/02729890122062622
    1. Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating-scale valuations. Med Decis Making. (1997) 17:208–16. 10.1177/0272989X9701700212

Source: PubMed

3
订阅